Advanced in Adenoid Cystic Carcinoma

Dr. David J. Sher

Radiation Oncology
University Of Texas Southwestern Medical Center At Dallas
2280 Inwood Rd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 3 Trials
Advanced in Adenoid Cystic Carcinoma
University Of Texas Southwestern Medical Center At Dallas
2280 Inwood Rd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Sher is a Radiation Oncologist in Dallas, Texas. Dr. Sher is rated as an Advanced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, and Gastrostomy.

His clinical research consists of co-authoring 213 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MA
Hospital Affiliations
Parkland Health & Hospital System
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
2280 Inwood Rd, Dallas, TX 75235
Other Locations
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
5201 Harry Hines Blvd, Dallas, TX 75235
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6201 Harry Hines Blvd, Dallas, TX 75235
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6202 Harry Hines Blvd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Enrollment Status: Recruiting
Publish Date: April 22, 2025
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 4 Less Clinical Trials

213 Total Publications

Response to Fiorica.
Response to Fiorica.
Journal: Journal of the National Cancer Institute
Published: September 22, 2025
Similar Doctors
Distinguished in Adenoid Cystic Carcinoma
Dr. Wilhelm J. Lubbe
Radiation Oncology
Distinguished in Adenoid Cystic Carcinoma
Dr. Wilhelm J. Lubbe
Radiation Oncology

North Dallas Radiation Oncology Center

5948 W Parker Rd, Ste 100, 
Plano, TX 
 (15.7 miles away)
972-972-8778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wilhelm Lubbe is a Radiation Oncologist in Plano, Texas. Dr. Lubbe is rated as an Advanced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Prostate Cancer, Familial Prostate Cancer, and Acinic Cell Carcinoma of Salivary Glands.

Distinguished in Adenoid Cystic Carcinoma
Dr. Brennen S. Cheek
Radiation Oncology
Distinguished in Adenoid Cystic Carcinoma
Dr. Brennen S. Cheek
Radiation Oncology

Texas Oncology, P.A.

3410 Worth Street, Suite 100, 
Dallas, TX 
 (4.0 miles away)
972-449-0540
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brennen Cheek is a Radiation Oncologist in Dallas, Texas. Dr. Cheek has been practicing medicine for over 32 years and is rated as an Advanced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Acinic Cell Carcinoma of Salivary Glands, Metastatic Brain Tumor, and Primitive Neuroectodermal Tumor (PNET).

Advanced in Adenoid Cystic Carcinoma
Dr. Jared D. Sturgeon
Radiation Oncology
Advanced in Adenoid Cystic Carcinoma
Dr. Jared D. Sturgeon
Radiation Oncology

Texas Center For Proton Therapy

1501 W Royal Ln, 
Irving, TX 
 (9.4 miles away)
469-513-5500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jared Sturgeon is a Radiation Oncologist in Irving, Texas. Dr. Sturgeon is rated as an Advanced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Nasopharyngeal Carcinoma, Acinic Cell Carcinoma of Salivary Glands, and Salivary Gland Tumors.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sher's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile